nodes	percent_of_prediction	percent_of_DWPC	metapath
Etomidate—SLC2A1—mammary gland—lung cancer	0.0189	0.242	CbGeAlD
Etomidate—Hypoxia—Gefitinib—lung cancer	0.015	0.0619	CcSEcCtD
Etomidate—SLC2A1—respiratory system—lung cancer	0.0126	0.162	CbGeAlD
Etomidate—Respiratory failure—Crizotinib—lung cancer	0.0107	0.0441	CcSEcCtD
Etomidate—SLC2A1—epithelium—lung cancer	0.0105	0.135	CbGeAlD
Etomidate—Respiratory failure—Pemetrexed—lung cancer	0.00976	0.0403	CcSEcCtD
Etomidate—Respiratory failure—Gefitinib—lung cancer	0.0097	0.0401	CcSEcCtD
Etomidate—SLC2A1—trachea—lung cancer	0.00931	0.119	CbGeAlD
Etomidate—Hypoxia—Vinorelbine—lung cancer	0.00775	0.032	CcSEcCtD
Etomidate—SLC2A1—bone marrow—lung cancer	0.00738	0.0947	CbGeAlD
Etomidate—Pseudoephedrine—IL2—lung cancer	0.00716	0.639	CrCbGaD
Etomidate—SLC2A1—lung—lung cancer	0.00669	0.0858	CbGeAlD
Etomidate—Hypoxia—Gemcitabine—lung cancer	0.00622	0.0257	CcSEcCtD
Etomidate—Respiratory failure—Topotecan—lung cancer	0.00586	0.0242	CcSEcCtD
Etomidate—Bradycardia—Crizotinib—lung cancer	0.00536	0.0222	CcSEcCtD
Etomidate—Respiratory failure—Vinorelbine—lung cancer	0.00501	0.0207	CcSEcCtD
Etomidate—Arrhythmia—Crizotinib—lung cancer	0.0047	0.0194	CcSEcCtD
Etomidate—SLC2A1—lymph node—lung cancer	0.00457	0.0587	CbGeAlD
Etomidate—Laryngospasm—Etoposide—lung cancer	0.00452	0.0187	CcSEcCtD
Etomidate—Arrhythmia—Pemetrexed—lung cancer	0.0043	0.0178	CcSEcCtD
Etomidate—Arrhythmia—Gefitinib—lung cancer	0.00427	0.0177	CcSEcCtD
Etomidate—Hiccups—Irinotecan—lung cancer	0.00406	0.0168	CcSEcCtD
Etomidate—Respiratory failure—Gemcitabine—lung cancer	0.00403	0.0166	CcSEcCtD
Etomidate—Apnoea—Etoposide—lung cancer	0.00398	0.0165	CcSEcCtD
Etomidate—CYP11B2—lymph node—lung cancer	0.00392	0.0502	CbGeAlD
Etomidate—Hiccups—Cisplatin—lung cancer	0.00369	0.0152	CcSEcCtD
Etomidate—Hypertension—Pemetrexed—lung cancer	0.00362	0.0149	CcSEcCtD
Etomidate—Arrhythmia—Teniposide—lung cancer	0.00348	0.0144	CcSEcCtD
Etomidate—Respiratory failure—Paclitaxel—lung cancer	0.00337	0.0139	CcSEcCtD
Etomidate—Hypoxia—Methotrexate—lung cancer	0.00318	0.0132	CcSEcCtD
Etomidate—Hypotension—Gefitinib—lung cancer	0.00317	0.0131	CcSEcCtD
Etomidate—Hypertension—Teniposide—lung cancer	0.00293	0.0121	CcSEcCtD
Etomidate—Pain—Pemetrexed—lung cancer	0.00292	0.0121	CcSEcCtD
Etomidate—Pain—Gefitinib—lung cancer	0.00291	0.012	CcSEcCtD
Etomidate—Respiratory failure—Docetaxel—lung cancer	0.00286	0.0118	CcSEcCtD
Etomidate—Tachycardia—Teniposide—lung cancer	0.0027	0.0112	CcSEcCtD
Etomidate—GABRB2—lung—lung cancer	0.00261	0.0335	CbGeAlD
Etomidate—Hypotension—Teniposide—lung cancer	0.00259	0.0107	CcSEcCtD
Etomidate—Arrhythmia—Erlotinib—lung cancer	0.00255	0.0106	CcSEcCtD
Etomidate—Hyperventilation—Doxorubicin—lung cancer	0.00254	0.0105	CcSEcCtD
Etomidate—Apnoea—Methotrexate—lung cancer	0.00239	0.00986	CcSEcCtD
Etomidate—Vomiting—Crizotinib—lung cancer	0.00238	0.00983	CcSEcCtD
Etomidate—Convulsion—Vinblastine—lung cancer	0.00224	0.00927	CcSEcCtD
Etomidate—Hypertension—Vinblastine—lung cancer	0.00224	0.00924	CcSEcCtD
Etomidate—Arrhythmia—Vinorelbine—lung cancer	0.00221	0.00913	CcSEcCtD
Etomidate—Vomiting—Pemetrexed—lung cancer	0.00217	0.00898	CcSEcCtD
Etomidate—Vomiting—Gefitinib—lung cancer	0.00216	0.00893	CcSEcCtD
Etomidate—Bradycardia—Irinotecan—lung cancer	0.00208	0.00858	CcSEcCtD
Etomidate—Respiratory failure—Methotrexate—lung cancer	0.00206	0.00851	CcSEcCtD
Etomidate—Bradycardia—Cisplatin—lung cancer	0.00188	0.00779	CcSEcCtD
Etomidate—Hypertension—Vinorelbine—lung cancer	0.00186	0.00768	CcSEcCtD
Etomidate—Arrhythmia—Irinotecan—lung cancer	0.00182	0.00753	CcSEcCtD
Etomidate—Pain—Vinblastine—lung cancer	0.00181	0.00747	CcSEcCtD
Etomidate—Arrhythmia—Gemcitabine—lung cancer	0.00177	0.00733	CcSEcCtD
Etomidate—Vomiting—Teniposide—lung cancer	0.00176	0.00728	CcSEcCtD
Etomidate—Pain—Topotecan—lung cancer	0.00176	0.00725	CcSEcCtD
Etomidate—Hiccups—Doxorubicin—lung cancer	0.00175	0.00724	CcSEcCtD
Etomidate—Pain—Erlotinib—lung cancer	0.00174	0.00718	CcSEcCtD
Etomidate—Tachycardia—Vinorelbine—lung cancer	0.00171	0.00708	CcSEcCtD
Etomidate—Bradycardia—Paclitaxel—lung cancer	0.00169	0.00699	CcSEcCtD
Etomidate—Arrhythmia—Cisplatin—lung cancer	0.00165	0.00683	CcSEcCtD
Etomidate—Hypotension—Vinorelbine—lung cancer	0.00164	0.00678	CcSEcCtD
Etomidate—Fenoprofen—PTGS2—lung cancer	0.00158	0.141	CrCbGaD
Etomidate—Hypertension—Irinotecan—lung cancer	0.00153	0.00633	CcSEcCtD
Etomidate—Pain—Vinorelbine—lung cancer	0.0015	0.00621	CcSEcCtD
Etomidate—Hypertension—Gemcitabine—lung cancer	0.00149	0.00617	CcSEcCtD
Etomidate—Arrhythmia—Paclitaxel—lung cancer	0.00149	0.00614	CcSEcCtD
Etomidate—CYP19A1—lymph node—lung cancer	0.00145	0.0186	CbGeAlD
Etomidate—Fenoprofen—ALB—lung cancer	0.0014	0.125	CrCbGaD
Etomidate—Convulsion—Cisplatin—lung cancer	0.0014	0.00577	CcSEcCtD
Etomidate—Hypotension—Irinotecan—lung cancer	0.00135	0.00559	CcSEcCtD
Etomidate—Vomiting—Vinblastine—lung cancer	0.00134	0.00555	CcSEcCtD
Etomidate—Hypotension—Gemcitabine—lung cancer	0.00132	0.00545	CcSEcCtD
Etomidate—Vomiting—Topotecan—lung cancer	0.00131	0.00539	CcSEcCtD
Etomidate—Vomiting—Erlotinib—lung cancer	0.00129	0.00534	CcSEcCtD
Etomidate—Tachycardia—Cisplatin—lung cancer	0.00128	0.0053	CcSEcCtD
Etomidate—Convulsion—Etoposide—lung cancer	0.00128	0.00529	CcSEcCtD
Etomidate—Hypertension—Etoposide—lung cancer	0.00127	0.00527	CcSEcCtD
Etomidate—Arrhythmia—Docetaxel—lung cancer	0.00126	0.0052	CcSEcCtD
Etomidate—Convulsion—Paclitaxel—lung cancer	0.00125	0.00518	CcSEcCtD
Etomidate—Hypertension—Paclitaxel—lung cancer	0.00125	0.00516	CcSEcCtD
Etomidate—Pain—Irinotecan—lung cancer	0.00124	0.00512	CcSEcCtD
Etomidate—Hypotension—Cisplatin—lung cancer	0.00123	0.00508	CcSEcCtD
Etomidate—Pain—Gemcitabine—lung cancer	0.00121	0.00499	CcSEcCtD
Etomidate—Tachycardia—Etoposide—lung cancer	0.00118	0.00486	CcSEcCtD
Etomidate—Tachycardia—Paclitaxel—lung cancer	0.00115	0.00476	CcSEcCtD
Etomidate—Hypotension—Etoposide—lung cancer	0.00113	0.00465	CcSEcCtD
Etomidate—Pain—Cisplatin—lung cancer	0.00112	0.00465	CcSEcCtD
Etomidate—Vomiting—Vinorelbine—lung cancer	0.00112	0.00461	CcSEcCtD
Etomidate—Hypotension—Paclitaxel—lung cancer	0.0011	0.00456	CcSEcCtD
Etomidate—Convulsion—Docetaxel—lung cancer	0.00106	0.00439	CcSEcCtD
Etomidate—Hypertension—Docetaxel—lung cancer	0.00106	0.00438	CcSEcCtD
Etomidate—Pethidine—ALB—lung cancer	0.00106	0.0946	CrCbGaD
Etomidate—Pain—Etoposide—lung cancer	0.00103	0.00426	CcSEcCtD
Etomidate—Pain—Paclitaxel—lung cancer	0.00101	0.00417	CcSEcCtD
Etomidate—Tachycardia—Docetaxel—lung cancer	0.000977	0.00404	CcSEcCtD
Etomidate—Hypotension—Docetaxel—lung cancer	0.000936	0.00387	CcSEcCtD
Etomidate—Vomiting—Irinotecan—lung cancer	0.000921	0.00381	CcSEcCtD
Etomidate—Vomiting—Gemcitabine—lung cancer	0.000897	0.00371	CcSEcCtD
Etomidate—Bradycardia—Doxorubicin—lung cancer	0.000895	0.0037	CcSEcCtD
Etomidate—Pain—Docetaxel—lung cancer	0.000856	0.00354	CcSEcCtD
Etomidate—Vomiting—Cisplatin—lung cancer	0.000836	0.00346	CcSEcCtD
Etomidate—Arrhythmia—Doxorubicin—lung cancer	0.000786	0.00325	CcSEcCtD
Etomidate—Convulsion—Methotrexate—lung cancer	0.000766	0.00317	CcSEcCtD
Etomidate—Vomiting—Etoposide—lung cancer	0.000766	0.00317	CcSEcCtD
Etomidate—Vomiting—Paclitaxel—lung cancer	0.000751	0.0031	CcSEcCtD
Etomidate—Hypotension—Methotrexate—lung cancer	0.000674	0.00279	CcSEcCtD
Etomidate—Convulsion—Doxorubicin—lung cancer	0.000663	0.00274	CcSEcCtD
Etomidate—Hypertension—Doxorubicin—lung cancer	0.000661	0.00273	CcSEcCtD
Etomidate—Vomiting—Docetaxel—lung cancer	0.000637	0.00263	CcSEcCtD
Etomidate—Pain—Methotrexate—lung cancer	0.000617	0.00255	CcSEcCtD
Etomidate—Tachycardia—Doxorubicin—lung cancer	0.00061	0.00252	CcSEcCtD
Etomidate—Hypotension—Doxorubicin—lung cancer	0.000584	0.00241	CcSEcCtD
Etomidate—Pain—Doxorubicin—lung cancer	0.000534	0.00221	CcSEcCtD
Etomidate—Vomiting—Methotrexate—lung cancer	0.000459	0.0019	CcSEcCtD
Etomidate—Vomiting—Doxorubicin—lung cancer	0.000397	0.00164	CcSEcCtD
Etomidate—GABRB2—Transmembrane transport of small molecules—APOA1—lung cancer	0.000123	0.000184	CbGpPWpGaD
Etomidate—SLC2A1—Disease—NRAS—lung cancer	0.000123	0.000184	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—GSTA1—lung cancer	0.000123	0.000184	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—GSTM1—lung cancer	0.000123	0.000184	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—ANXA1—lung cancer	0.000122	0.000182	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—ABCC3—lung cancer	0.000122	0.000182	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—SDC4—lung cancer	0.000118	0.000177	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—SRC—lung cancer	0.000118	0.000177	CbGpPWpGaD
Etomidate—GABRB2—Transmission across Chemical Synapses—HRAS—lung cancer	0.000118	0.000176	CbGpPWpGaD
Etomidate—SLC2A1—Disease—MAPK3—lung cancer	0.000118	0.000176	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—AKR1C1—lung cancer	0.000118	0.000176	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—PTHLH—lung cancer	0.000118	0.000176	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—PTEN—lung cancer	0.000117	0.000175	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—CYP1A1—lung cancer	0.000116	0.000174	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—DUSP3—lung cancer	0.000116	0.000173	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—ERCC2—lung cancer	0.000116	0.000173	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—PTEN—lung cancer	0.000116	0.000173	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—APP—lung cancer	0.000116	0.000173	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—GSTP1—lung cancer	0.000115	0.000172	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—VEGFA—lung cancer	0.000115	0.000172	CbGpPWpGaD
Etomidate—SLC2A1—Disease—MYC—lung cancer	0.000115	0.000171	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—UGT1A1—lung cancer	0.000114	0.000171	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—RHEB—lung cancer	0.000114	0.00017	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—MMP1—lung cancer	0.000114	0.00017	CbGpPWpGaD
Etomidate—GABRG2—Transmembrane transport of small molecules—APOA1—lung cancer	0.000113	0.000168	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—CAT—lung cancer	0.000112	0.000168	CbGpPWpGaD
Etomidate—SLC2A1—Disease—EGFR—lung cancer	0.000112	0.000168	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—EP300—lung cancer	0.000111	0.000167	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—ANXA1—lung cancer	0.000111	0.000165	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—AKT1—lung cancer	0.00011	0.000165	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—EP300—lung cancer	0.00011	0.000165	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—GNG11—lung cancer	0.00011	0.000165	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—IL6—lung cancer	0.00011	0.000165	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—APOA1—lung cancer	0.00011	0.000164	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—ABCB1—lung cancer	0.000109	0.000163	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—MAPK3—lung cancer	0.000109	0.000163	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—APOA1—lung cancer	0.000109	0.000163	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—GRM8—lung cancer	0.000108	0.000161	CbGpPWpGaD
Etomidate—GABRG2—Transmission across Chemical Synapses—HRAS—lung cancer	0.000108	0.000161	CbGpPWpGaD
Etomidate—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—lung cancer	0.000107	0.00016	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—TYMS—lung cancer	0.000107	0.00016	CbGpPWpGaD
Etomidate—SLC2A1—Disease—KRAS—lung cancer	0.000106	0.000158	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—GSTM1—lung cancer	0.000106	0.000158	CbGpPWpGaD
Etomidate—ADRA2B—GPCR ligand binding—POMC—lung cancer	0.000106	0.000158	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—ALDOA—lung cancer	0.000105	0.000157	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—APP—lung cancer	0.000105	0.000157	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—SKI—lung cancer	0.000104	0.000156	CbGpPWpGaD
Etomidate—GABRB2—Transmembrane transport of small molecules—CREBBP—lung cancer	0.000104	0.000156	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—NCOA3—lung cancer	0.000102	0.000152	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—CYP1A1—lung cancer	0.0001	0.00015	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	0.0001	0.00015	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—APOA1—lung cancer	0.0001	0.000149	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—ERCC2—lung cancer	9.96e-05	0.000149	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—PIK3CG—lung cancer	9.92e-05	0.000148	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—ABCG2—lung cancer	9.91e-05	0.000148	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—ADCY1—lung cancer	9.91e-05	0.000148	CbGpPWpGaD
Etomidate—GABRA1—Transmembrane transport of small molecules—APOA1—lung cancer	9.84e-05	0.000147	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—EGF—lung cancer	9.81e-05	0.000147	CbGpPWpGaD
Etomidate—GABRB2—Transmembrane transport of small molecules—ALB—lung cancer	9.75e-05	0.000146	CbGpPWpGaD
Etomidate—SLC2A1—Disease—PIK3CA—lung cancer	9.73e-05	0.000145	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—ENO2—lung cancer	9.71e-05	0.000145	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—HPGDS—lung cancer	9.71e-05	0.000145	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—PPP2R1B—lung cancer	9.65e-05	0.000144	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	9.57e-05	0.000143	CbGpPWpGaD
Etomidate—GABRG2—Transmembrane transport of small molecules—CREBBP—lung cancer	9.53e-05	0.000142	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—POMC—lung cancer	9.52e-05	0.000142	CbGpPWpGaD
Etomidate—GABRA1—Transmission across Chemical Synapses—HRAS—lung cancer	9.43e-05	0.000141	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—GSTT1—lung cancer	9.42e-05	0.000141	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—GCLC—lung cancer	9.31e-05	0.000139	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—CYP2A6—lung cancer	9.31e-05	0.000139	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	9.28e-05	0.000139	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—CREBBP—lung cancer	9.2e-05	0.000138	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—PIK3CG—lung cancer	9.13e-05	0.000136	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PXN—lung cancer	9.07e-05	0.000136	CbGpPWpGaD
Etomidate—GABRB2—Neuronal System—HRAS—lung cancer	9.03e-05	0.000135	CbGpPWpGaD
Etomidate—SLC2A1—Disease—HRAS—lung cancer	9e-05	0.000135	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—PIK3CA—lung cancer	8.99e-05	0.000134	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—AVP—lung cancer	8.98e-05	0.000134	CbGpPWpGaD
Etomidate—GABRG2—Transmembrane transport of small molecules—ALB—lung cancer	8.92e-05	0.000133	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—GRP—lung cancer	8.88e-05	0.000133	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—AKR1C1—lung cancer	8.88e-05	0.000133	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—OXTR—lung cancer	8.88e-05	0.000133	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—ENO1—lung cancer	8.83e-05	0.000132	CbGpPWpGaD
Etomidate—GABRB2—Transmembrane transport of small molecules—RAF1—lung cancer	8.82e-05	0.000132	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	8.8e-05	0.000132	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—PIK3CD—lung cancer	8.72e-05	0.00013	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—POMC—lung cancer	8.69e-05	0.00013	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—ALB—lung cancer	8.68e-05	0.00013	CbGpPWpGaD
Etomidate—SLC2A1—Disease—IL6—lung cancer	8.62e-05	0.000129	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—APOA1—lung cancer	8.61e-05	0.000129	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—ALB—lung cancer	8.61e-05	0.000129	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—CREBBP—lung cancer	8.46e-05	0.000126	CbGpPWpGaD
Etomidate—GABRA1—Transmembrane transport of small molecules—CREBBP—lung cancer	8.33e-05	0.000125	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—GNG11—lung cancer	8.32e-05	0.000124	CbGpPWpGaD
Etomidate—GABRG2—Neuronal System—HRAS—lung cancer	8.26e-05	0.000124	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	8.25e-05	0.000123	CbGpPWpGaD
Etomidate—ADRA2B—GPCR ligand binding—CXCL8—lung cancer	8.17e-05	0.000122	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—AVP—lung cancer	8.16e-05	0.000122	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—PIK3CA—lung cancer	8.15e-05	0.000122	CbGpPWpGaD
Etomidate—GABRG2—Transmembrane transport of small molecules—RAF1—lung cancer	8.07e-05	0.000121	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—PIK3CD—lung cancer	8.02e-05	0.00012	CbGpPWpGaD
Etomidate—SLC2A1—Disease—AKT1—lung cancer	7.95e-05	0.000119	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—CYP2E1—lung cancer	7.92e-05	0.000118	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—ALB—lung cancer	7.92e-05	0.000118	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—VEGFC—lung cancer	7.92e-05	0.000118	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—PIK3CG—lung cancer	7.86e-05	0.000118	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—NQO1—lung cancer	7.83e-05	0.000117	CbGpPWpGaD
Etomidate—GABRA1—Transmembrane transport of small molecules—ALB—lung cancer	7.8e-05	0.000117	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—RAF1—lung cancer	7.79e-05	0.000116	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	7.67e-05	0.000115	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—PIK3CB—lung cancer	7.6e-05	0.000114	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	7.6e-05	0.000114	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—POMC—lung cancer	7.49e-05	0.000112	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—ADCY1—lung cancer	7.48e-05	0.000112	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—AKT1—lung cancer	7.35e-05	0.00011	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—CREBBP—lung cancer	7.29e-05	0.000109	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PPP2R1B—lung cancer	7.29e-05	0.000109	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—SMARCA4—lung cancer	7.29e-05	0.000109	CbGpPWpGaD
Etomidate—GABRA1—Neuronal System—HRAS—lung cancer	7.22e-05	0.000108	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—STK11—lung cancer	7.06e-05	0.000106	CbGpPWpGaD
Etomidate—GABRA1—Transmembrane transport of small molecules—RAF1—lung cancer	7.05e-05	0.000105	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—HSPB1—lung cancer	7.03e-05	0.000105	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—PIK3CB—lung cancer	6.99e-05	0.000105	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—IL2—lung cancer	6.98e-05	0.000104	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PTHLH—lung cancer	6.95e-05	0.000104	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—PTGS2—lung cancer	6.93e-05	0.000104	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—PIK3CD—lung cancer	6.91e-05	0.000103	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—ALB—lung cancer	6.82e-05	0.000102	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—AKT1—lung cancer	6.66e-05	9.95e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—lung cancer	6.63e-05	9.91e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—ANXA1—lung cancer	6.54e-05	9.77e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—GSTP1—lung cancer	6.53e-05	9.76e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—CAT—lung cancer	6.36e-05	9.5e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—FLT1—lung cancer	6.33e-05	9.46e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—EP300—lung cancer	6.32e-05	9.45e-05	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—PIK3CG—lung cancer	6.27e-05	9.38e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—EP300—lung cancer	6.27e-05	9.37e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—APP—lung cancer	6.2e-05	9.26e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—NOTCH3—lung cancer	6.2e-05	9.26e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—ABCB1—lung cancer	6.18e-05	9.24e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—FGF9—lung cancer	6.15e-05	9.19e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—SRC—lung cancer	6.09e-05	9.11e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—TYMS—lung cancer	6.07e-05	9.08e-05	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—PTEN—lung cancer	6.04e-05	9.03e-05	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—PIK3CB—lung cancer	6.03e-05	9.01e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—GSTM1—lung cancer	6e-05	8.97e-05	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—PTGS2—lung cancer	5.97e-05	8.93e-05	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—POMC—lung cancer	5.97e-05	8.92e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—VEGFA—lung cancer	5.93e-05	8.87e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—JUNB—lung cancer	5.87e-05	8.77e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—NRAS—lung cancer	5.86e-05	8.76e-05	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—EP300—lung cancer	5.76e-05	8.61e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—PIK3CG—lung cancer	5.69e-05	8.51e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—CYP1A1—lung cancer	5.69e-05	8.51e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—ERCC2—lung cancer	5.64e-05	8.44e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—MAPK3—lung cancer	5.61e-05	8.39e-05	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—PIK3CD—lung cancer	5.51e-05	8.24e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—POMC—lung cancer	5.42e-05	8.1e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—STK11—lung cancer	5.33e-05	7.97e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—IL6R—lung cancer	5.29e-05	7.91e-05	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—PTEN—lung cancer	5.21e-05	7.78e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—FOXO3—lung cancer	5.14e-05	7.69e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—KRAS—lung cancer	5.05e-05	7.54e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—MAP2K1—lung cancer	5.04e-05	7.53e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—PIK3CD—lung cancer	5.01e-05	7.48e-05	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—EP300—lung cancer	4.97e-05	7.42e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—APOA1—lung cancer	4.88e-05	7.3e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—AVP—lung cancer	4.82e-05	7.2e-05	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—PIK3CB—lung cancer	4.81e-05	7.18e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	4.67e-05	6.99e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—IGF1R—lung cancer	4.64e-05	6.93e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—PIK3CA—lung cancer	4.64e-05	6.93e-05	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—CXCL8—lung cancer	4.62e-05	6.9e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—HES1—lung cancer	4.56e-05	6.81e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—TP53—lung cancer	4.48e-05	6.7e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—RAF1—lung cancer	4.47e-05	6.68e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—PIK3CG—lung cancer	4.46e-05	6.66e-05	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—IL2—lung cancer	4.41e-05	6.6e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—PIK3CB—lung cancer	4.36e-05	6.52e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—HRAS—lung cancer	4.29e-05	6.41e-05	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—PIK3CA—lung cancer	4.26e-05	6.37e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—POMC—lung cancer	4.24e-05	6.34e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—CXCL8—lung cancer	4.19e-05	6.27e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—ERBB3—lung cancer	4.17e-05	6.23e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—CREBBP—lung cancer	4.13e-05	6.18e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—IL2—lung cancer	4.01e-05	5.99e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—TERT—lung cancer	3.99e-05	5.97e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—PIK3CD—lung cancer	3.92e-05	5.86e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—FGFR1—lung cancer	3.88e-05	5.8e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—ALB—lung cancer	3.87e-05	5.78e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—HIF1A—lung cancer	3.82e-05	5.71e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—AKT1—lung cancer	3.79e-05	5.66e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—APOA1—lung cancer	3.68e-05	5.51e-05	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—PIK3CA—lung cancer	3.67e-05	5.49e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—KDR—lung cancer	3.65e-05	5.46e-05	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—AKT1—lung cancer	3.48e-05	5.21e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—PIK3CB—lung cancer	3.41e-05	5.11e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—PTGS2—lung cancer	3.38e-05	5.06e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—APC—lung cancer	3.36e-05	5.03e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PIK3CG—lung cancer	3.36e-05	5.03e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—KIT—lung cancer	3.36e-05	5.03e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—NRAS—lung cancer	3.36e-05	5.03e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—EGF—lung cancer	3.33e-05	4.97e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—MAPK3—lung cancer	3.22e-05	4.82e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—POMC—lung cancer	3.2e-05	4.79e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—BRAF—lung cancer	3.16e-05	4.73e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—IL6R—lung cancer	3.12e-05	4.67e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CREBBP—lung cancer	3.12e-05	4.66e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—EGFR—lung cancer	3.06e-05	4.58e-05	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—AKT1—lung cancer	3e-05	4.49e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—MAP2K1—lung cancer	2.98e-05	4.45e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PIK3CD—lung cancer	2.96e-05	4.42e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—PTEN—lung cancer	2.95e-05	4.41e-05	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—PIK3CA—lung cancer	2.93e-05	4.38e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—KRAS—lung cancer	2.9e-05	4.33e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—EP300—lung cancer	2.81e-05	4.21e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—PIK3CA—lung cancer	2.66e-05	3.98e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—MDM2—lung cancer	2.65e-05	3.96e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—RAF1—lung cancer	2.64e-05	3.95e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—ERBB2—lung cancer	2.61e-05	3.91e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—MTOR—lung cancer	2.58e-05	3.85e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PIK3CB—lung cancer	2.58e-05	3.85e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CXCL8—lung cancer	2.48e-05	3.7e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—HRAS—lung cancer	2.46e-05	3.68e-05	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—AKT1—lung cancer	2.39e-05	3.58e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CASP3—lung cancer	2.37e-05	3.54e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—IL2—lung cancer	2.37e-05	3.54e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—IL6—lung cancer	2.36e-05	3.52e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CCND1—lung cancer	2.31e-05	3.45e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—JUN—lung cancer	2.3e-05	3.44e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—MMP9—lung cancer	2.24e-05	3.35e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CDKN1A—lung cancer	2.23e-05	3.34e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PTEN—lung cancer	2.23e-05	3.33e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—AKT1—lung cancer	2.17e-05	3.25e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—EP300—lung cancer	2.12e-05	3.18e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—PIK3CA—lung cancer	2.08e-05	3.11e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—SRC—lung cancer	2.07e-05	3.09e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—VEGFA—lung cancer	2.01e-05	3.01e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—STAT3—lung cancer	1.99e-05	2.98e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—NRAS—lung cancer	1.99e-05	2.97e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—MAPK3—lung cancer	1.9e-05	2.85e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—MYC—lung cancer	1.85e-05	2.77e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—EGFR—lung cancer	1.81e-05	2.71e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—KRAS—lung cancer	1.71e-05	2.56e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—AKT1—lung cancer	1.7e-05	2.54e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PIK3CA—lung cancer	1.57e-05	2.35e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—TP53—lung cancer	1.52e-05	2.27e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—HRAS—lung cancer	1.45e-05	2.17e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—IL6—lung cancer	1.39e-05	2.08e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—AKT1—lung cancer	1.28e-05	1.92e-05	CbGpPWpGaD
